Navigation Links
Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
Date:2/23/2010

RESEARCH TRIANGLE PARK, N.C., Feb. 23 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that founder and CEO George Painter, Ph.D., will join representatives from government, industry and academia in an Institute of Medicine Workshop focusing on improving innovation around the discovery and development of new products needed to undertake medical countermeasures (e.g. vaccines, drugs, and diagnostics) when responding to public health emergencies.  The workshop, "The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval," is being held at The National Academy of Sciences Building in Washington, D.C., on February 23-24, 2010.  

The workshop will examine federal policies and activities relevant to the discovery and through the approval of products integral to undertaking medical countermeasures for responding to public health emergencies, such as a bioterrorist attack or a pandemic outbreak with the potential to rapidly overwhelm existing public health and medical systems.  Dr. Painter will participate on a panel convened to address procuring and improving scientific innovation based on an assessment of national biodefense priorities.  The panel, "Opportunities for enhancing translation of basic science: models to improve innovation that responds to national priorities," will also examine current investment in basic research and identify potential other models to optimize the medical countermeasures product pipeline.  

Chimerix's lead compound, CMX001, is being developed as a biodefense countermeasure in the event of smallpox release in addition to use in antiviral applications.  CMX001 is also currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections for immunocompromised patient populations.  

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  CMX157 is a late-stage preclinical candidate being developed as a potential once-weekly nucleoside analogue against HIV infections.  Building on the company's extensive chemical library, Chimerix also has an aggressive effort in translational medicine addressing malaria, dengue fever and other public health needs.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.

SOURCE Chimerix, Inc.

Back to top

RELATED LINKS
http://www.chimerix-inc.com

'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix to Present at Two Upcoming Investor Conferences
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
6. CORD:USE Cord Blood Bank Congratulates Team Member Hal Broxmeyer, Ph.D., on his Election as President of the American Society of Hematology
7. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
8. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
9. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. TechniScan Cofounder to Speak at SPIE Medical Imaging Conference About Ground-Breaking Science Behind the Companys Ultrasound Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):